Cerebral Palsy

• Disruption of corticospinal tract development and myelination: Injury to developing white matter (particularly periventricular white matter in preterm infants) or gray matter structures involved in motor control (motor cortex, basal ganglia, cerebellum) disrupts the normal hierarchical organization of motor pathways. This leads to loss of normal inhibitory control, resulting in hyperreflexia, increased muscle tone (spasticity), and release of primitive reflexes that normally suppress with maturation.

• Abnormal neurotransmitter regulation and synaptic dysfunction: Perinatal brain injury causes imbalances in inhibitory (GABA, glycine) and excitatory (glutamate) neurotransmission. Excessive glutamatergic activity during hypoxic-ischemic injury causes excitotoxicity and neuronal death. Survivors develop persistent alterations in neurotransmitter receptor expression and signaling, contributing to spasticity through reduced inhibitory tone on motor neurons and increased motor neuron excitability.

• Selective vulnerability of white matter and specific neuronal populations: Oligodendrocytes and premyelinating axons in the periventricular region are particularly susceptible to hypoxic-ischemic injury, free radical damage, and inflammatory cytokine-mediated injury. Damage to thalamocortical projections and intracortical connections disrupts normal sensorimotor integration, proprioceptive feedback, and motor planning mechanisms. In dyskinetic CP, basal ganglia involvement impairs the balance between direct (facilitatory) and indirect (inhibitory) motor pathways, resulting in involuntary movements.

• Periventricular leukomalacia (PVL) from hypoxia-ischemia, inflammation, or infection
• Intraventricular hemorrhage (IVH), particularly grades III–IV with periventricular hemorrhagic infarction
• Chorioamnionitis and fetal infection (cytomegalovirus, toxoplasmosis)
• Postnatal infections (sepsis, meningitis)
• Bronchopulmonary dysplasia-associated hypoxia

• Severe birth asphyxia with Apgar score ≤3 at 5 minutes
• Neonatal seizures, metabolic acidosis, hypoglycemia
• Meconium aspiration syndrome
• Maternal-fetal infections (intrauterine infection, ascending infection)
• Placental abnormalities (abruption, infarction)
• Severe intrauterine growth restriction

• Polymicrogyria, schizencephaly, lissencephaly, cortical dysplasia
• Corpus callosum abnormalities
• Cerebellar hypoplasia or atrophy
• Holoprosencephaly

• Head trauma and traumatic brain injury
• Meningitis or encephalitis
• Hypoxic-ischemic encephalopathy from near-drowning, severe infection, cardiac arrest
• Kernicterus from severe hyperbilirubinemia

Intrauterine infections (TORCH)

• Cytomegalovirus (most common infectious cause)
• Rubella, toxoplasmosis, herpes simplex virus
• Zika virus (associated with microcephaly and CP)

Maternal factors and prenatal risk factors

• Maternal seizure disorder or status epilepticus
• Maternal hyperthyroidism
• Intrauterine growth restriction
• Multiple gestations (particularly twin-twin transfusion)
• Fetal infections and inflammatory markers (elevated IL-6, TNF-α)

Motor abnormalities—classification by predominant motor pattern

• Spastic CP (75–80% of cases): Characterized by hypertonia with velocity-dependent increase in muscle tone (clasp-knife phenomenon), hyperreflexia, and positive Babinski sign. Subtypes include unilateral (hemiplegia), bilateral lower extremity (diplegia, most common in preterm infants), or generalized (quadriplegia). Patients demonstrate increased tone in antigravity muscles: hip and knee flexors, plantarflexors, adductors, and internal rotators.

• Dyskinetic CP (10–15% of cases): Characterized by involuntary movements including choreoathetosis, dystonia, or ballismus that worsen with emotion and voluntary movement and resolve during sleep. Often associated with basal ganglia involvement (particularly in kernicterus).

• Ataxic CP (5–10% of cases): Characterized by hypotonia, incoordination, intention tremor, and dysmetria with cerebellar dysfunction. Gait is wide-based and unsteady; nystagmus may be present.

• Mixed types: Combination of spasticity and dyskinesia or ataxia.

Limb distribution patterns

• Monoplegia: Single limb involvement (rare, usually reflects cortical injury)
• Hemiplegia: One side of body (most common after term birth asphyxia; associated with contralateral motor cortex or internal capsule injury)
• Diplegia: Primarily lower extremities (most common in preterm infants with PVL; lower extremities more medial in periventricular distribution)
• Quadriplegia: All four limbs (most severe; associated with generalized brain injury)

Associated impairments and comorbidities

• Cognitive dysfunction: Intellectual disability in 30–50% (higher with quadriplegia, lower with isolated hemiplegia); normal intelligence in many patients with spastic hemiplegia or diplegia

• Seizure disorders: Present in 30–40%, higher with cortical injury or quadriplegia; manifests as focal seizures, generalized tonic-clonic seizures, or infantile spasms in severe cases

• Visual impairments: Strabismus (20%), refractive errors, cortical visual impairment (particularly with periventricular injury), nystagmus (especially ataxic CP)

• Hearing loss: Sensorineural hearing loss in 5–10%, particularly with kernicterus or severe intrauterine infection

• Speech and language disorders: Dysarthria (35%), apraxia, language delays; severity correlates with motor severity

• Feeding and swallowing dysfunction: Oral motor dysfunction, aspiration risk, gastroesophageal reflux, drooling

• Orthopedic deformities: Contractures (from sustained spasticity), subluxation or dislocation of hip (particularly in spastic quadriplegia and diplegia), scoliosis, equinovarus foot deformity, internal rotation of hips

• Pain: Musculoskeletal pain from spasticity and contractures; neuropathic pain in some patients

• Bladder and bowel dysfunction: Neurogenic bladder, incontinence, constipation

• Growth and nutritional issues: Failure to thrive, nutritional deficiency, particularly with swallowing dysfunction

• Presence of abnormal tone (spasticity, dystonia, or hypotonia) and abnormal movement patterns that persist and become more evident as the child matures (motor abnormality does not resolve)
• Non-progressive nature of the underlying brain injury (though motor manifestations evolve with development; "static encephalopathy" with dynamic clinical course)
• Absence of progressive neurologic decline; if deterioration occurs, alternative diagnoses must be considered (progressive metabolic disorder, neurodegenerative disease, spinal cord pathology)
• Developmental delay in motor milestones appropriate to the severity and distribution of motor involvement (e.g., delayed head control, sitting, walking, fine motor skills)
• Abnormal primitive reflexes persistence: Moro reflex beyond 4–6 months, asymmetric tonic neck reflex (ATNR) persistence, absent or delayed parachute reflex
• Postural abnormalities: Excessive pronation of forearms, thumb-in-palm posturing, scissor gait pattern

Neuroimaging—essential for etiology and prognostication

• Cranial ultrasound (initial screening in neonates <4 weeks): Detects IVH, PVL (echogenic foci in periventricular region in acute phase, echolucency in cystic phase), ventricular dilatation, hydrocephalus. Limited sensitivity for cortical malformations.

• Magnetic resonance imaging (MRI)—gold standard for structural brain abnormality identification:
• MRI patterns associated with CP:
• Periventricular white matter injury/gliosis (most common with preterm birth)
• Cortical/subcortical stroke pattern (unilateral motor cortex or internal capsule infarction in hemiplegic CP)
• Cortical malformations (polymicrogyria, schizencephaly, lissencephaly)
• Basal ganglia involvement (particularly T1 hyperintensity suggesting chronic bilirubin deposition in kernicterus)
• Cerebellar atrophy (ataxic CP)
• Cystic PVL (periventricular cystic changes)
• Microcephaly
• Diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps help identify acute ischemic injury in neonatal period
• Advanced MRI techniques (tensor-based morphometry, voxel-based morphometry) can quantify white matter abnormalities and predict motor outcomes

• Computed tomography (CT): Less sensitive than MRI; useful when MRI contraindicated or to identify calcifications (toxoplasmosis, CMV)

• Metabolic and genetic screening (when etiology unclear and early-onset presentation):
• Serum and urine amino acids, organic acids (rule out inborn errors of metabolism)
• Very long-chain fatty acids (adrenoleukodystrophy)
• Plasma carnitine (organic acidurias)
• Lysosomal enzyme panels (when malformation present)
• Genetic testing: Chromosomal microarray for associated genetic abnormalities; whole exome sequencing for monogenic causes

• Serum bilirubin and unbound bilirubin (when bilirubin encephalopathy suspected, particularly with dyskinetic presentation)

• Infectious serology and PCR (intrauterine infection workup):
• CMV IgM, PCR (urine CMV PCR highly sensitive in first 3 weeks)
• Toxoplasmosis serology, PCR
• Rubella serology
• Zika virus serology/PCR (in endemic areas with prenatal exposure)

• Thyroid function tests (TSH, free T4) when maternal hyperthyroidism history present

Electroencephalography (EEG)

• Not diagnostic for CP but useful for seizure detection and characterization
• May show focal abnormalities (slowing, epileptiform discharges) consistent with brain injury localization
• Serial EEG helpful in early neonatal prognostication

Prognostic assessment—predictive factors for motor outcome

• Early indicators of poor prognosis: Profound hypotonia at 3 months, persistence of primitive reflexes beyond expected age, inability to sit by 12 months (suggests lower limb spasticity and structural brain injury), early seizure onset, quadriplegic pattern
• Early indicators of better prognosis: Normal tone by 3 months, isolated hemiplegia or diplegia, intact cognition, absence of seizures, preserved primitive reflex suppression

Overview of management approach

Spasticity management—pharmacological

• Baclofen (first-line oral agent):
• Mechanism: GABA-B agonist increasing presynaptic inhibition of motor neurons and reducing excitatory neurotransmitter release
• Dosing: Initial 5–15 mg/day in divided doses, titrate to 40–80 mg/day (maximum 120 mg/day); monitor for sedation, hypotonia, rebound spasticity with abrupt withdrawal
• Intrathecal baclofen (ITB) pump: Reserved for severe spasticity unresponsive to oral agents; provides 100–1000 times higher spinal cord concentration with lower systemic effects; requires implantable pump and regular refills; effective particularly in spastic diplegia and quadriplegia

• Benzodiazepines (diazepam, lorazepam):
• Enhance GABAergic inhibition at spinal cord and brainstem level
• Limited use due to sedation, tolerance, dependence; reserved for acute spasticity exacerbation or adjunctive therapy
• Diazepam: 0.1–0.3 mg/kg/dose three times daily; maximum 40 mg/day

• Tizanidine:
• Alpha-2 adrenergic agonist reducing excitatory neurotransmitter release at spinal and brainstem levels
• Dosing: 2–4 mg three times daily (usual range 6–12 mg/day; maximum 36 mg/day)
• Advantages: Less sedation than baclofen; useful adjunct for cervical and upper extremity spasticity
• Monitor: Liver function (hepatotoxicity rare), hypotension, dry mouth

• Dantrolene sodium:
• Unique mechanism: Directly inhibits calcium release from sarcoplasmic reticulum in skeletal muscle (peripheral action, not CNS)
• Dosing: Initial 0.5–1 mg/kg/day, titrate by 0.5 mg/kg every 4–7 days to maximum 3 mg/kg/day (usually 100–400 mg/day in divided doses)
• Less commonly used than baclofen due to potential hepatotoxicity and need for liver function monitoring
• Particularly useful for focal spasticity; less systemic side effects

Spasticity management—injectable botulinum toxin

• Botulinum toxin A (BTA) (onabotulinumtoxinA, abobotulinumtoxinA):
• Mechanism: Blocks acetylcholine release at neuromuscular junction by cleaving SNARE proteins (blocks acetylcholine vesicle release)
• Indications: Focal to regional spasticity limiting function (equinovarus foot, thumb-in-palm, hip adductor contracture, hamstring spasticity)
• Dosing: 3–6 units/kg per muscle group (maximum single dose 400 units); repeat injections every 12 weeks as effect wanes; typical effect onset 3–7 days, peak effect at 4 weeks
• Gold standard for focal spasticity, particularly in combination with physical therapy and stretching
• Limitations: Cost, need for repeated injections, possible development of antibodies (neutralizing antibodies develop in 1–5%)
• Most effective when combined with orthoses and aggressive physiotherapy

Spasticity management—surgical interventions

• Selective dorsal rhizotomy (SDR):
• Surgical sectioning of

Musculoskeletal complications of sustained spasticity

• Hip displacement (subluxation → dislocation): unopposed adductor/iliopsoas pull on a hip that never bore normal weight produces progressive lateral migration; signaled by increasing adductor tone, loss of abduction range, and pain with perineal care. Risk rises steeply with GMFCS level; AACPDM-endorsed hip surveillance uses serial AP pelvis radiographs with measurement of the migration percentage.
• Contractures and equinus/equinovarus deformity: fixed shortening of muscle-tendon units once tone is chronic; the tell-tale finding is loss of passive range that no longer resolves under sedation or anesthesia.
• Neuromuscular scoliosis: long C-shaped curve from truncal tone imbalance, most common in spastic quadriplegia; may compromise sitting balance and pulmonary function.
• Osteopenia and fragility fractures: immobilization, poor nutrition, low vitamin D, and antiseizure drugs; suspect with unexplained irritability or swelling after minimal trauma.

Bulbar and systemic complications

• Aspiration pneumonia (emergency): oropharyngeal dyscoordination plus reflux; new fever, tachypnea, or hypoxemia in a child with drooling and coughing on feeds warrants urgent evaluation and is the leading cause of death in severe CP.
• Malnutrition/failure to thrive: prolonged feed times and aspiration risk; declining weight-for-age triggers swallow study and consideration of gastrostomy.
• Status epilepticus (emergency): cortical injury substrate; benzodiazepine first, per standard pediatric protocols.

Treatment-related complications

• Intrathecal baclofen withdrawal (emergency): pump failure, catheter kink, or empty reservoir causes abrupt loss of GABA-B inhibition — high fever, rebound rigidity, altered mental status, rhabdomyolysis, and DIC, closely mimicking neuroleptic malignant syndrome. Treat by restoring baclofen (oral/intrathecal) plus benzodiazepines; dantrolene alone is inadequate. Abrupt oral baclofen cessation can also cause seizures and hallucinations.
• Baclofen overdose (pump programming or dosing error): hypotonia, bradycardia, respiratory depression, coma — supportive airway management.
• Botulinum toxin distant spread: FDA boxed warning; dysphagia, ptosis, and generalized weakness days to weeks after injection.
• Dantrolene hepatotoxicity and tizanidine hypotension/transaminitis require monitoring; benzodiazepines cause sedation and tolerance.
• Selective dorsal rhizotomy: transient sensory dysesthesias, late spinal deformity, and unmasking of underlying weakness.

• Preterm + periventricular leukomalacia = spastic diplegia: descending corticospinal fibers to the legs run most medially near the ventricles, so periventricular injury spares the arms relatively. Look for scissoring gait, toe-walking, and brisk reflexes in a former 28-weeker.
• Early hand preference before 12 months is pathologic: it is the classic first clue to spastic hemiplegic CP (contralateral MCA-territory perinatal stroke), not precocious development. This is a favorite distractor.
• Kernicterus is the one association examiners test: severe unconjugated hyperbilirubinemia damages the globus pallidus and subthalamic nucleus, producing dyskinetic (choreoathetoid) CP with sensorineural hearing loss and impaired upgaze, and T1 hyperintense globus pallidus on MRI. Cognition is often preserved.
• Best next step when the diagnosis is suspected clinically: brain MRI to define the injury pattern and etiology — the diagnosis itself is clinical, and imaging is confirmatory/prognostic, not required to start therapy. Early referral to physical/occupational therapy should not wait for imaging.
• Non-progressive is the defining word: loss of previously acquired milestones, worsening tone over years, organomegaly, or a fluctuating course points away from CP toward a leukodystrophy, mitochondrial disease, dopa-responsive dystonia, or a spinal cord lesion. A trial of levodopa is reasonable when "spastic diplegia" shows diurnal variation.
• Intrapartum asphyxia explains only a minority of CP: the ACOG/AAP neonatal encephalopathy consensus emphasizes that most cases are not attributable to intrapartum events, and a low Apgar alone does not establish causation.
• Two obstetric/neonatal interventions reduce CP risk: antenatal magnesium sulfate for fetal neuroprotection with imminent preterm birth (ACOG) and therapeutic hypothermia for moderate-to-severe hypoxic-ischemic encephalopathy in near-term/term neonates (AAP).
• Function is graded, not guessed: the Gross Motor Function Classification System (GMFCS, levels I–V) drives prognosis, hip surveillance intensity, and therapy goals.